Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lirametostat + ipilimumab in advanced solid tumors
NCT03525795Phase 1Completed
- Sponsor
- Constellation Pharmaceuticals
- Start
- Dec 2017
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lirametostat in solid tumor (advanced stage), melanoma, non-small cell lung cancer (NSCLC) and 2 more, sponsored by Constellation Pharmaceuticals. Primary endpoints: Frequency of Dose-limiting toxicities at 1 year and Objective Response Rate at 1 year. Started Dec 2017; status: completed.
02
Drugs
lirametostat
03
Conditions
solid tumor (advanced stage)melanomanon-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03525795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03525795.